帕妥珠单抗联合曲妥珠单抗治疗HER2阳性乳腺癌的效果

Effect of Pertuzumab Combined with Trastuzumab in Treatment of HER2 Positive Breast Cancer

目的:探讨帕妥珠单抗联合曲妥珠单抗在人表皮生长因子受体-2(HER2)阳性乳腺癌患者治疗中的应用效果。方法:选取2020年1月—2022年4月福建省三明市沙县区总医院诊治的HER2阳性乳腺癌患者76例作为研究对象,按照随机数字表法分为联合组与对照组,各38例。对照组给予曲妥珠单抗治疗,联合组在对照组治疗基础上给予帕妥珠单抗治疗,比较两组临床疗效、不良反应发生情况、炎症因子表达及生活质量。结果:联合组总有效率为86.8%,高于对照组的47.4%(P<0.05);联合组胃肠道反应、心脏毒性反应、皮肤反应、血液毒性反应发生率与对照组比较,差异无统计学意义(P>0.05);联合组血清IL-6、IL-8含量低于对照组(P<0.05)。联合组生理机能、情感职能、社会功能、生理职能、躯体疼痛评分高于对照组(P<0.05)。结论:帕妥珠单抗联合曲妥珠单抗应用于HER2阳性乳腺癌患者的疗效确切,可抑制炎症因子,提高生活质量,且不增加不良反应发生率。

Objective:To investigate the application effect of pertuzumab combined with trastuzumab in the treatment of patients with human epidermal growth factor receptor-2(HER2)positive breast cancer.Methods:A total of 76 patients with HER2-positive breast cancer diagnosed and treated in Shaxian District General Hospital of Sanming City,Fujian Province from January 2020 to April 2022 were selected as the research objects and divided into the combination group and the control group according to the random number table method,with 38 cases in each group.The control group was treated with trastuzumab,and the combined group was treated with pertuzumab on the basis of the control group.The clinical eficacy,adverse reactions,expression of inflammatory factors and quality of life were compared between the two groups.Results:The total effective rate of the combined group was 86.8%,which was higher than 47.4%of the control group(P<0.05).There was no significant difference in the incidence of gastrointestinal reaction,cardiotoxicity reaction,skin reaction and hematotoxicity reaction between the combined group and the control group(P>0.05).The contents of serum IL-6 and IL-8 in combined group were lower than those in control group(P<0.05).The scores of physiological function,emotional function,social function,physiological function and body pain in the combined group were higher than those in the control group(P<0.05).Conclusion:Patuzumab combined with trastuzumab is effective in patients with HER2 positive breast cancer.It can inhibit inflammatory factors,improve the quality of life,and does not increase the incidence of adverse reactions.